Enzalutamide

Type: Keyphrase
Name: Enzalutamide
First reported Apr 21 2014 - Updated Apr 21 2014 - 1 reports

Xtandi Shows Significant Benefit in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer

Xtandi® (enzalutamide) showed significant survival benefit in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 European Association of Urology (EAU) Congress in Stockholm, ... [Published CancerConnect.com - Apr 21 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Phase 3 PREVAIL Study Delivers Promising Results in Prostate Cancer Patients

The results of the Phase 3 PREVAIL study on enzalutamide showed significant benefit to prostate cancer patients including delaying the progression of metastatic disease, reducing the risk of death and delaying the start of cytotoxic chemotherapy.Enzalutamide ... [Published American Journal of Managed Care - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Articles Enzalutamide monotherpy in hormonenaive prostate cancer primary analysis of an openlabel singlearm phase 2 study

Our findings suggest that enzalutamide monotherapy in men with hormone-naive prostate cancer of varying severity provides a level of disease suppression, and was generally well tolerated. These findings provide a rationale for further investigation o ... [Published BioPortfolio - Apr 14 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 2 reports

Variant May Thwart New Tx for Prostate Ca

Related Biotechnology, Pharmaceutical and Healthcare NewsSAN DIEGO (MedPage Today) -- The presence of an androgen receptor variant in advanced prostate cancer cells identified patients unlikely to benefit from enzalutamide, a small clinical study sug ... [Published BioPortfolio - Apr 10 2014]
First reported Apr 09 2014 - Updated Apr 10 2014 - 2 reports

Biomarker for Resistance to Enzalutamide Prostate Cancer

SAN DIEGO — A new biomarker could help predict resistance to enzalutamide ( Xtandi ) in patients with prostate cancer, according to early data presented here at the American Association for Cancer Research 2014.The biomarker is androgen-receptor splice ... [Published Diabetes Care - Apr 10 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 2 reports

AACR Bloodbased biomarker may identify prostate cancers that will Be resistant to enzalutamide

Men with metastatic, castration-resistant prostate cancer who started treatment with the drug enzalutamide (Xtandi) and had a molecule called AR-V7 present in circulating tumour cells (CTCs) obtained prior to treatment had a worse response to enzalut ... [Published BioPortfolio - Apr 08 2014]
First reported Apr 05 2014 - Updated Apr 05 2014 - 1 reports

Calne man's bid to keep brother alive

9:00am Saturday 5th April 2014 in Latest NewsFundraiser Marc Fitchett wants to help prolong the life of his brotherBusinessman Marc Fitchett has set up an appeal to help his brother, Ian, who has prostate cancer and needs a life-extending drug not available ... [Published This Is Wiltshire - Apr 05 2014]
First reported Apr 03 2014 - Updated Apr 04 2014 - 8 reports

ASTELLAS ANNOUNCES MARKETING AUTHORISATION APPLICATION FOR XTANDI ENZALUTAMIDE FOR CHEMOTHERAPYNAVE METASTATIC PROSTATE CANCER pdf 83KB

Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: ASTELLAS ANNOUNCES MARKETING AUTHORISATION APPLICATION FOR XTANDI™ (ENZALUTAMIDE) FOR CHEMOTHERAPY-NAÏVE METASTATIC PROSTATE CANCER (pdf 83KB)NEXT ARTICLE More From BioPortfolio ... [Published BioPortfolio - Apr 04 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

NCCN gets $2.2m research funding to study enzalutamide in solid tumors

The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) has been awarded a $2.2m grant from Astellas Pharma and Medivation to develop a program to scientifically evaluate and ... ... [Published Big News Network - Apr 02 2014]
First reported Mar 31 2014 - Updated Apr 01 2014 - 3 reports

NCCN gets $2.2m research funding to study enzalutamide in solid tumors

The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) has been awarded a $2.2m grant from Astellas Pharma and Medivation to develop a program to scientifically evaluate and define the clinical effectiveness of enzalutamide in ... [Published PBR - News - Apr 01 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 3 reports

Astellas Wins Prostate Cancer Approval for Xtandi in Japan

Astellas Pharma Inc. announced that Astellas has obtained marketing approval of their oral androgen receptor signaling inhibitor, Xtandi capsules 40mg (enzalutamide) for the treatment of patients with castration-resistant prostate cancer in Japan. Astellas ... [Published BioPortfolio - Mar 25 2014]
First reported Mar 24 2014 - Updated Mar 25 2014 - 7 reports

Astellas Announces Marketing Approval in Japan for XTANDI enzalutamide Capsules an Advanced Prostate Cancer Treatment

Related Biotechnology, Pharmaceutical and Healthcare NewsTOKYO, March 24, 2014 /PRNewswire/ --Astellas Pharma Inc. (TSE: 4503) today announced that Astellas has obtained marketing approval of their oral androgen receptor signaling inhibitor, XTANDI® ... [Published BioPortfolio - Mar 25 2014]

Quotes

NEXT ARTICLE More From BioPortfolio on "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014"
NEXT ARTICLE More From BioPortfolio on "Xtandi Shows Significant Benefit in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer"
...Glenn Mattes, President and CEO of Arno Therapeutics, remarked, "Globally, prostate cancer is the second most common cancer in men, and the fifth leading cause of death from cancer in men, with an estimated 1.1 million new cases diagnosed and 307,000 deaths during 2012 alone, according to the International Agency for Research on Cancer. These numbers are staggering, and our ultimate goal is to evaluate onapristone in the subset of advanced CRPC patients who are more likely to respond to this personalized treatment, for which there is an immense unmet medical need. The trial marks Arno's second Phase I study actively enrolling this year and we are excited by the momentum generated thus far."
"Given the high UK prevalence of prostate cancer and also cardiovascular disease (CVD), it means that approximately 1 in 3 men with prostate cancer would have experienced a cardiovascular event" he said

More Content

All (131) | News (114) | Reports (0) | Blogs (15) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Metastatic Hormone Refractory Castration Resist... [Published BioPortfolio - Apr 22 2014]
Xtandi Shows Significant Benefit in Chemotherap... [Published BioPortfolio - Apr 21 2014]
Xtandi Shows Significant Benefit in Chemotherap... [Published CancerConnect.com - Apr 21 2014]
Arno Therapeutics enrolls first patient in Phas... [Published Individual.com - Apr 17 2014]
NICE gives partial backing to Ferring's prostat... [Published PMLive - Apr 16 2014]
Phase 3 PREVAIL Study Delivers Promising Result... [Published American Journal of Managed Care - Apr 15 2014]
Therapeutic options and multifaceted treatment ... [Published UroToday - Apr 15 2014]
Articles Enzalutamide monotherpy in hormonenaiv... [Published BioPortfolio - Apr 14 2014]
Variant May Thwart New Tx for Prostate Ca [Published BioPortfolio - Apr 10 2014]
Variant May Thwart New Tx for Prostate Ca [Published MedPageToday.com - medical news plus CME for ph ... - Apr 10 2014]
Biomarker for Resistance to Enzalutamide Prosta... [Published Diabetes Care - Apr 10 2014]
Possible Biomarker for Enzalutamide in Prostate... [Published Cancernetwork.com - Apr 09 2014]
Doncaster cancer deaths higher than national av... [Published Sheffield Star - Apr 09 2014]
Astellas Announces European Regulatory Submissi... [Published Asian Hospital & Healthcare Management - Apr 08 2014]
AACR Bloodbased biomarker may identify prostate... [Published BioPortfolio - Apr 08 2014]
Promising emerging agents for triple negative b... [Published Pharma Letter - Apr 08 2014]
Arno starts enrolling patients in Phase I/II tr... [Published PBR - News - Apr 08 2014]
Myriad Submits Premarket Approval to FDA for BR... [Published BioMedReports - Apr 08 2014]
Blood-based Biomarker May Identify Prostate Can... [Published American Association for Cancer Research - Apr 08 2014]
Arno Therapeutics Enrolls First Patient in a Ph... [Published Virtual Strategy Magazine - Apr 07 2014]
Arno Therapeutics : Enrolls First Patient in a ... [Published 4 Traders - Apr 07 2014]
Astellas submits MAA for wider use of prostate ... [Published Pharmaceutical Technology - Apr 07 2014]
Calne man's bid to keep brother alive [Published This Is Wiltshire - Apr 05 2014]
Metformin in prostate cancer, "Beyond the Abstr... [Published UroToday - Apr 05 2014]
Mechanism of action and clinical activity of ta... [Published UroToday - Apr 04 2014]
Astellas Medivation submit European Marketing A... [Published BioPortfolio - Apr 04 2014]
Astellas, Medivation submit European Marketing ... [Published News-Medical.Net - Apr 04 2014]
Therapeutic Class Overview: Newer Oral Anti And... [Published NewsRX - Apr 04 2014]
Discount Packages on Global Trends and Developm... [Published PR.com Press Releases - Apr 04 2014]
Discount Packages on Global Trends and Developm... [Published ListFree.Org - Apr 04 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Variant May Thwart New Tx for Prostate Ca [Published MedPageToday.com - medical news plus CME for ph ... - Apr 10 2014]
SAN DIEGO (MedPage Today) -- The presence of an androgen receptor variant in advanced prostate cancer cells identified patients unlikely to benefit from enzalutamide, a small clinical study suggested. ...
Arno starts enrolling patients in Phase I/II tr... [Published PBR - News - Apr 08 2014]
Arno Therapeutics (ARNI), a US-based biopharmaceutical company, has initiated enrolling patients in a Phase I/II trial (NCT02049190) evaluating its lead compound 'onapristone' in men with advanced castration-resistant prostate cancer (CRPC) after failure ...
Discount Packages on Global Trends and Developm... [Published PR.com Press Releases - Apr 04 2014]
New York, NY, April 04, 2014 --( PR.com )-- The global biotechnology and pharmaceutical market have seen significant positive sentiments in the recent years, especially with innovation contributing to the availability of a range of new treatments for ...
Astellas Announces European Regulatory Submissi... [Published PR Newswire: Health - Apr 03 2014]
TOKYO and SAN FRANCISCO, April 3, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503) and Medivation Inc. (NASDAQ: MDVN) today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) ...
Astellas Announces Marketing Authorisation Appl... [Published PRESSEMITTEILUNGEN - Apr 03 2014]
Tokyo (ots/PRNewswire) – Astellas Pharma Inc. today announces the submission of a variation to amend the Marketing Authorisation Application for XTANDI(TM) (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate ...
1 2 3

Press Releases

sort by: Date | Relevance
Astellas Announces Marketing Approval in Japan ... [Published Financial Services - Mar 24 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.